Most drugs are a single word. His is the whole conversation.
At a lab bench in Pittsburgh, Larry Brown's team grows a rare population of cells harvested from donated full-term placentas, lets them talk, and then takes everything the cells say and throws the cells away. What is left is ST266: a cell-free solution carrying hundreds of growth factors and cytokines at the levels a living body would actually use. That inversion - keep the message, discard the messenger - is the bet his career now rides on.
Brown is Executive Vice President of R&D and Chief Scientific Officer at Noveome Biotherapeutics, the clinical-stage biopharma he joined in 2012. His assignment has stayed remarkably constant: take ST266 from an interesting result in a notebook and drag it, study by study and filing by filing, into a clinic where it can treat patients. In 2023 the FDA cleared Noveome to begin a Phase 1-2 trial of ST266 in necrotizing enterocolitis in premature infants. In 2024 the U.S. Patent Office issued patent 12,121,546, covering treatment of systemic inflammatory responses. The proof of principle is becoming a product.
What makes the approach unusual is its refusal to simplify. The pharmaceutical instinct is to isolate the one active ingredient and discard the rest. Brown's preclinical work pointed the other way. Strip ST266 down and the neuroprotective effect falls apart - the full complement of proteins is doing the work together, like a committee that only functions at quorum.
A pedigree most scientists only cite
Brown earned his doctorate in biochemistry and bioengineering at MIT under Robert Langer, the most-cited engineer in history and a founding figure of controlled drug delivery. He then trained in the surgical research laboratory of the late Judah Folkman at Children's Hospital Boston, the surgeon-scientist who first argued that tumors recruit their own blood supply. Two mentors, two revolutions in biomedicine. Decades later, Langer would join Noveome's board of directors, which means Brown answers, in part, to the man who signed off on his thesis.
Three decades of getting molecules to the right address
Before Noveome, Brown spent more than 35 years across startups and large pharma learning a single hard problem: delivery. As Vice President of Research and corporate head of drug delivery at Baxter Healthcare, and earlier in scientific leadership at Alkermes and other biotechs, he worked on getting therapeutic proteins, monoclonal antibodies, nucleic acids, and transdermal formulations to behave once they entered the body. He conceived and built novel formulations and whole product portfolios, and accumulated more than 100 publications and a stack of key patents along the way.
That history explains one of ST266's quieter tricks. The program studies intranasal, nose-to-brain delivery - routing the biologic past the blood-brain barrier that stops most large molecules at the door. A man who spent a career figuring out how to deliver other people's drugs ended up helping invent both the cargo and the route.
ST266 is a complex mixture of hundreds of large and small biomolecules secreted by a novel population of cells, created by the proprietary culturing of amnion-derived epithelial cells collected from donated full-term placentas.
Why this, why now
Noveome positions ST266 as a platform rather than a single drug - one biologic aimed at inflammation, neuroprotection, cell recovery and healing across multiple indications, from optic neuritis to systemic inflammatory response. For Brown, the appeal is the breadth: a multi-targeted therapy for conditions that single-target drugs have struggled to reach. The FDA has granted ST266 both Orphan Drug and Rare Pediatric Disease designations in necrotizing enterocolitis, the kind of recognition that tends to follow a credible scientific case rather than a marketing one.
He is also a familiar face on the conference circuit, an invited speaker at international meetings on drug delivery, diabetes, and biotechnology, where he tends to talk about the unglamorous engineering of getting a biologic to work where it is needed. He keeps a foot in Cambridge too, with collaborations tied to MIT's Deshpande Center for technological innovation.
The story Brown is writing is patient by design. Biologics do not move at software speed, and a secretome made from cultured human cells invites scrutiny at every step. His job is the long translation: from a result that worked once, to a manufacturing process that works every time, to a trial that proves it works in people. He has been at it since 2012, and the gates - patents, designations, an FDA clearance - keep opening one at a time.
Four facts worth keeping
His scientific lineage runs through Robert Langer and Judah Folkman - two of the most consequential names in biomedical engineering and cancer biology.
The core idea inverts cell therapy: keep what the cells make, throw the cells away.
He spent a career perfecting drug delivery, then helped build a drug delivered nose-to-brain to slip past the bloodstream's guard.
His PhD advisor now sits on his company's board - the examiner became the director.